Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors block intestinal enzymes that digest starch and disaccharides, slowing carbohydrate absorption and delaying postprandial glucose spikes. These drugs also stimulate GLP-1 secretion from intestinal L-cells, further reducing blood glucose. This dual mechanism makes them effective adjuncts for type 2 diabetes management.

Acarbose is minimally absorbed by the intestine, while miglitol, which resembles glucose structurally, shows 50%-100% absorption. Both drugs are renally eliminated. Acarbose may cause mild to moderate hepatic transaminase elevation, whereas miglitol does not. Despite absorption differences, both effectively delay carbohydrate digestion and are administered in 25-, 50-, or 100-mg tablets before meals.

Common gastrointestinal adverse effects include malabsorption, flatulence, diarrhea, and abdominal cramping or bloating. These occur because undigested carbohydrates reach the colon, where bacterial fermentation produces gas and osmotic effects cause diarrhea. Dose adjustment based on glucose levels and gastrointestinal symptoms can help minimize these effects in patients taking these inhibitors.

α-glucosidase inhibitors alone do not typically cause hypoglycemia. However, when combined with insulin or insulin secretagogues, they increase hypoglycemia risk because these agents further reduce glucose availability. Patients receiving concurrent therapy require careful glucose monitoring and potential dose adjustments to prevent dangerous low blood glucose episodes.

Acarbose decreases digoxin absorption, while miglitol reduces absorption of propranolol and ranitidine. These interactions occur because delayed carbohydrate digestion alters intestinal pH and transit time, affecting drug bioavailability. Clinicians should monitor therapeutic drug levels and consider dosage adjustments when α-glucosidase inhibitors are co-prescribed with these medications.

Patients with stage 4 renal failure should not receive α-glucosidase inhibitors because both acarbose and miglitol are renally eliminated and accumulate in severe kidney disease. Additionally, these drugs are contraindicated in patients with inflammatory bowel disease or severe malabsorption syndromes, as they worsen gastrointestinal dysfunction.

Despite their efficacy in delaying carbohydrate digestion, α-glucosidase inhibitors have limited U.S. prescription use due to modest glucose-lowering benefits compared to other oral antidiabetic agents and significant gastrointestinal side effects. However, they remain valuable adjuncts to diet and exercise for type 2 diabetic patients struggling to reach glycemic targets and can be combined with other agents without causing weight gain.